Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07569926 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 6 sites
  2. Primary endpoints: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 5 of 7 entries
    • Site details revised at 2 of 6 sites
  3. Recruitment opened
    • Start date changed from estimate of Jun 1, 2026 to Aug 31, 2026
    • Site details revised at 6 of 6 sites
    v3
  4. Study sites: 4 to 6
    • Secondary endpoints revised (7)
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence
Trial Details
NCT Number NCT07569926
Lead Sponsor Blue Earth Diagnostics
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 142 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov